The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: A preclinical and pharmacokinetic study

Oncotarget

Volumn 6, Issue 1, 2015, Pages 510-521

  Kathawala, Rishil J ^a,h   Wei, Liuya ^a,b   Anreddy, Nagaraju ^a   Chen, Kang ^c,d,e,f   Patel, Atish ^a   Alqahtani, Saeed ^g   Zhang, Yun Kai ^a   Wang, Yi Jun ^a   Sodani, Kamlesh ^a   Kaddoumi, Amal ^g   Ashby, Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b WEIFANG MEDICAL UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

ABC transporters; ABCC10; NVP BHG712; Paclitaxel; Tyrosine kinase inhibitors

Indexed keywords

4 METHYL 3 (1 METHYL 6 (PYRIDIN 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 YLAMINO) N [3 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE; EPHRIN RECEPTOR B4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ABCC10 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; NVP BH6712; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TUMOR LEVEL; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SOLID TUMOR; TREATMENT DURATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PYRAZOLES; PYRIMIDINES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921419237     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2638     Document Type: Article

References (43)

1. Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, Sun YL, Kaddoumi A, Ashby CR, Jr. and Chen ZS. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Molecular cancer therapeutics. 2014; 13(3):714-723.
2. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58.
3. Kathawala RJ, Wang YJ, Ashby CR, Jr. and Chen ZS. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese journal of cancer. 2014; 33(5):223-230.
4. Sodani K, Patel A, Kathawala RJ and Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 2012; 31(2):58-72.
5. Blagosklonny MV and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999; 83(2):151-156.
6. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003; 22(47):7280-7295.
7. Dumontet C and Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(3):1061-1070.
8. Drukman S and Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (review). Int J Oncol. 2002; 21(3):621-628.
9. Yin S, Bhattacharya R and Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010; 9(2):327-335.
10. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG and Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007; 453(5):675-684.
11. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, Maeda H, Sato S and Ueda R. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Molecular cancer therapeutics. 2008; 7(5):1150-1155.
12. Wangari-Talbot J and Hopper-Borge E. Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of cancer research updates. 2013; 2(4):265-282.
13. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT and Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. Journal of experimental therapeutics & oncology. 2004; 4(3):239-246.
14. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG and Slatter JG. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2006; 36(10-11):963-988.
15. Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, Ferretti M, Schmiedeberg N, Wood JM, Furet P and Imbach P. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010; 13(3):259-267.
16. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM and Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer letters. 2013; 328(2):307-317.
17. Wang YJ, Zhang YK, Kathawala RJ and Chen ZS. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers. 2014; 6(4):1925-1952.
18. Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JN and Chen ZS. Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules. 2014; 19(9):13848-13877.
19. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR, Jr., Chen X, Kruh GD and Chen ZS. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochemical pharmacology. 2009; 77(6):993-1001.
20. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA and Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer. 2005; 4(1):18.
21. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JW, Fu LW and Chen ZS. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2010; 79(2):154-161.
22. Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J and Chen ZS. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One. 2009; 4(10):e7520.
23. Keizer HG and Joenje H. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J Natl Cancer Inst. 1989; 81(9):706-709.
24. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML and Rustum YM. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res. 1996; 2(2):369-377.
25. Bessho Y, Oguri T, Ozasa H, Uemura T, Sakamoto H, Miyazaki M, Maeno K, Sato S and Ueda R. ABCC10/ MRP7 is associated with vinorelbine resistance in nonsmall cell lung cancer. Oncology reports. 2009; 21(1):263-268.
26. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M and Furusawa K. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. International journal of oncology. 2007; 30(2):393-401.
27. Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG and Kruh GD. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer research. 2011; 71(10):3649-3657.
28. Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, Chen ZS and Chen X. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future oncology. 2013.
29. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987; 47(4):936-942.
30. Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen ZS and Fu LW. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer letters. 2014.
31. Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Jr., Ambudkar SV, Bates SE, Fu LW and Chen ZS. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. The international journal of biochemistry & cell biology. 2014; 51:111-119.
32. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Jr., Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS and Fu LW. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008; 68(19):7905-7914.
33. Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP and Fu LW. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol. 2004; 56(8):1061-1066.
34. Wang DS, Patel A, Shukla S, Zhang YK, Wang YJ, Kathawala RJ, Robey RW, Zhang L, Yang DH, Talele TT, Bates SE, Ambudkar SV, Xu RH and Chen ZS. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget. 2014; 5(12):4529-4542.
35. Zhang H, Patel A, Ma SL, Li XJ, Zhang YK, Yang PQ, Kathawala RJ, Wang YJ, Anreddy N, Fu LW and Chen ZS. In vitro, in vivo and ex-vivo characterization of ibrutinib: A potent inhibitor of MRP1 efflux function. British journal of pharmacology. 2014.
36. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT and Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical pharmacology. 2014; 89(1):52-61.
37. Gill KK, Nazzal S and Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011; 79(2):276-284.
38. Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT and Chen ZS. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical pharmacology. 2014; 90(4):367-378.
39. Zhang H, Zhang YK, Wang YJ, Kathawala RJ, Patel A, Zhu H, Sodani K, Talele TT, Ambudkar SV, Chen ZS and Fu LW. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. Cancer science. 2014; 105(8):1071-1078.
40. Sun YL, Kathawala RJ, Singh S, Zheng K, Talele TT, Jiang WQ and Chen ZS. Zafirlukast antagonizes ATPbinding cassette subfamily G member 2-mediated multidrug resistance. Anticancer Drugs. 2012; 23(8):865-873.
41. Kathawala RJ, Chen JJ, Zhang YK, Wang YJ, Patel A, Wang DS, Talele TT, Ashby CR, Jr. and Chen ZS. Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. International journal of oncology. 2014; 44(5):1634-1642.
42. Deng W, Dai CL, Chen JJ, Kathawala RJ, Sun YL, Chen HF, Fu LW and Chen ZS. Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology reports. 2013; 29(6):2479-2485.
43. Wang DS, Patel A, Sim HM, Zhang YK, Wang YJ, Kathawala RJ, Zhang H, Talele TT, Ambudkar SV, Xu RH and Chen ZS. ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. Journal of cellular biochemistry. 2014; 115(8):1381-1391.